tiprankstipranks
Trending News
More News >
NATCO Pharma Limited (IN:NATCOPHARM)
:NATCOPHARM
India Market
Advertisement

NATCO Pharma Limited (NATCOPHARM) AI Stock Analysis

Compare
11 Followers

Top Page

IN:NATCOPHARM

NATCO Pharma Limited

(NATCOPHARM)

Select Model
Select Model
Select Model
Outperform 74 (OpenAI - 4o)
Rating:74Outperform
Price Target:
₹1,086.00
▲(34.36% Upside)
NATCO Pharma Limited's stock is rated well due to its strong financial performance and attractive valuation. The company shows robust revenue growth and profitability, with effective cash management and low leverage. Technical indicators are mixed, suggesting some caution, but the stock's low P/E ratio indicates it may be undervalued. Absence of earnings call data and significant corporate events means these factors did not influence the score.

NATCO Pharma Limited (NATCOPHARM) vs. iShares MSCI India ETF (INDA)

NATCO Pharma Limited Business Overview & Revenue Model

Company DescriptionNATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
How the Company Makes MoneyNATCO Pharma Limited generates revenue primarily through the sale of its generic pharmaceutical products and APIs. The company's revenue streams include domestic sales in India and exports to international markets, with a significant portion of its income derived from the oncology segment. NATCO also engages in partnerships and collaborations with other pharmaceutical companies to co-develop and market products, enhancing its market reach and revenue potential. Additionally, the company invests in research and development to innovate and expand its product portfolio, ensuring a steady flow of new and competitive offerings in the pharmaceutical market.

NATCO Pharma Limited Financial Statement Overview

Summary
NATCO Pharma Limited demonstrates strong financial health with robust revenue growth, high profitability margins, and a solid balance sheet. It effectively converts earnings into cash and maintains low leverage, indicating financial stability. However, attention is needed on capital expenditures and managing liabilities to ensure sustained performance.
Income Statement
85
Very Positive
NATCO Pharma Limited shows strong income statement performance with notable revenue growth of 10.7% from 2024 to 2025. The company's gross profit margin is robust at 65.7%, and the net profit margin stands at a healthy 42.6%. The EBIT margin of 44.3% and EBITDA margin of 57.6% in 2025 reflect efficient cost management and strong operational performance. However, a slight decline in gross profit from 2024 indicates a need for careful monitoring.
Balance Sheet
78
Positive
NATCO Pharma Limited has a strong balance sheet with a low debt-to-equity ratio of 0.04, indicating low financial leverage. The return on equity is impressive at 24.8%, showcasing effective use of shareholders' funds. The equity ratio is robust at 88.1%, emphasizing financial stability. However, a decrease in gross profit and increasing liabilities over the years highlight potential areas of concern.
Cash Flow
82
Very Positive
The cash flow statement highlights strong free cash flow growth of 67.4% from 2024 to 2025, indicating improved cash-generating capability. The operating cash flow to net income ratio of 0.97 suggests efficient conversion of profits into cash. Furthermore, the free cash flow to net income ratio of 0.76 reflects effective cash management. Despite the positive trends, careful attention to capital expenditures is advised to maintain free cash flow growth.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue43.96B44.30B40.02B27.07B19.05B20.56B
Gross Profit33.95B29.10B32.53B20.80B12.23B15.24B
EBITDA23.30B25.50B18.80B10.40B3.63B6.07B
Net Income16.98B18.85B13.88B7.15B1.70B4.41B
Balance Sheet
Total Assets0.0086.31B69.06B56.57B51.09B47.92B
Cash, Cash Equivalents and Short-Term Investments24.97B24.97B17.78B11.25B7.60B8.18B
Total Debt0.002.79B3.86B1.76B4.32B2.84B
Total Liabilities-76.12B10.19B10.53B-34.80B8.46B6.68B
Stockholders Equity76.12B76.07B58.53B48.74B42.64B41.22B
Cash Flow
Free Cash Flow0.0014.28B8.72B6.43B-1.96B442.00M
Operating Cash Flow0.0016.97B12.12B8.49B465.00M2.99B
Investing Cash Flow0.00-14.14B-10.33B-4.77B-53.00M-1.03B
Financing Cash Flow0.00-2.11B-2.47B-3.63B348.00M-1.86B

NATCO Pharma Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price808.25
Price Trends
50DMA
871.92
Negative
100DMA
896.49
Negative
200DMA
951.89
Negative
Market Momentum
MACD
-18.66
Positive
RSI
36.68
Neutral
STOCH
30.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NATCOPHARM, the sentiment is Negative. The current price of 808.25 is below the 20-day moving average (MA) of 839.21, below the 50-day MA of 871.92, and below the 200-day MA of 951.89, indicating a bearish trend. The MACD of -18.66 indicates Positive momentum. The RSI at 36.68 is Neutral, neither overbought nor oversold. The STOCH value of 30.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NATCOPHARM.

NATCO Pharma Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
₹145.28B8.560.62%4.14%3.72%
69
Neutral
₹74.91B21.390.48%16.94%4.90%
59
Neutral
₹135.16B52.500.23%14.82%19.38%
56
Neutral
₹174.83B37.770.46%8.12%-16.64%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
₹553.79B73.470.13%10.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:NATCOPHARM
NATCO Pharma Limited
808.25
-619.32
-43.38%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
1,925.60
170.06
9.69%
IN:GLS
Glenmark Life Sciences Limited
919.75
-250.12
-21.38%
IN:JUBLPHARMA
Jubilant Pharmova Limited
1,086.25
-92.51
-7.85%
IN:MARKSANS
Marksans Pharma Limited
164.25
-121.64
-42.55%
IN:RAINBOW
Rainbow Childrens Medicare Limited
1,313.50
-83.82
-6.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 26, 2025